| Abstrakt: |
Researchers at GlaxoSmithKline plc have conducted a study on a new tuberculosis vaccine called M72/AS01E. The vaccine showed promising results in a Phase IIb trial, protecting half of the latently-infected adults against progression to pulmonary tuberculosis. In preclinical studies on mice, the vaccine induced polyfunctional, Th1-cytokine-expressing T cells in blood and lungs. The researchers also found that the vaccine induced cross-reactive systemic T-cell responses to a nonvaccine antigen. These findings could guide future clinical development of the vaccine. [Extracted from the article] |
